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Summary
Heart transplantation is the treatment of choice for many patients with end-stage heart failure. Its success, however, is limited by organ
shortage, side effects of immunosuppressive drugs, and chronic rejection. Gene therapy is conceptually appealing for applications in
transplantation, as the donor organ is genetically manipulated ex vivo before transplantation. Localised expression of immunomodulatory
genes aims to create a state of immune privilege within the graft, which could eliminate the need for systemic immunosuppression. In this review,
recent advances in the development of gene therapy in heart transplantation are discussed. Studies in animal models have demonstrated that
genetic modification of the donor heart with immunomodulatory genes attenuates ischaemia—reperfusion injury and rejection. Alternatively,
bone marrow-derived cells genetically engineered with donor-type major histocompatibility complex (MHC) class I or II promote donor-specific
hyporesponsiveness. Genetic engineering of naı¨ve T cells or dendritic cells may induce regulatory T cells and regulatory dendritic cells. Despite
encouraging results in animal models, however, clinical gene therapy trials in heart transplantation have not yet been started. The best vector
and gene to be delivered remain to be identified. Pre-clinical studies in non-human primates are needed. Nonetheless, the potential of gene
therapy as an adjunct therapy in transplantation is essentially intact.
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Organ transplantation is the treatment of choice for many
patients with end-stage organ failure. However, the success
of organ transplantation is limited by several factors,
including a severe shortage of donor organs, side effects
of immunosuppressive drugs, and chronic allograft rejection.
Multi-drug immunosuppressive regimens currently used in
human transplant recipients are associated with an increased
risk of malignancy and opportunistic infections, a metabolic
syndrome characterised by insulin resistance and dyslipi-
daemia, and drug-specific toxicity (e.g., cyclosporin-related
nephrotoxicity). Most importantly, immunosuppressive regi-
mens have been quite effective in preventing acute
rejection, but have shown limited efficacy against chronic
rejection. A retrospective analysis of the United Network for
Organ Sharing (UNOS) dataset revealed that, among first-
time cardiac transplant recipients (n = 14,401 between the§ Financial support: Swiss Science Foundation, Swiss Cardiology Foundation,
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was 94%, 87% and 75% for the younger group (<60 years of
age), and 93%, 84% and 69% for the older group [1]. The drop
in survival rates beyond the first year after transplantation is
particularly frustrating and calls for the development of new
strategies. Among them, gene therapy has attracted
considerable attention over the past decade. Proof-of-
principle studies in animal models have indicated that gene
therapy in organ transplantation is feasible. However,
encouraging experimental results have not translated into
clinical applications so far. Several issues regarding both gene
transfer vectors and the most effective gene to be delivered
remain unanswered.
Transplantation may be uniquely amenable to gene
therapy applications for several reasons. First, the ther-
apeutic gene can be introduced into the donor organ under
controlled ex vivo conditions immediately after organ
procurement. The therapeutic factor is produced by the
graft itself, which could maximise graft protection while
minimising systemic side effects. Over the past few years,
gene transfer vectors with a potential for long-term gene
expression have been developed. As an example, we have
observed myocardial expression of a green fluorescent
protein (GFP) reporter gene 1 year after adeno-associatedurgery. Published by Elsevier B.V. All rights reserved.
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Fig. 1. Schematic illustration of the variety of modalities based on genetic
modification of the donor organ. A viral vector carries the therapeutic gene
(black) to the nucleus, where it is integrated in a chromosome when integrated
factors such as retroviruses or lentiviruses are used (alternatively, the gene is not
integrated but remains in an extra chromosomal state within the nucleus when
using other viral vectors, e.g., adenovectors, or nonviral vehicles). Examples of
therapeutic genes encoding secreted factors (e.g., CTLA4Ig), cell surface mole-
cules (e.g., MHC class I or II), or intracellular factors (e.g., HO-1, immunosup-
pressivecytokines)areshown.Alternatively,thevectormaydeliverantisenseODN
or ribozyme that inhibit expression of pathogenic genes (abbreviations: see text).
Table 1
Selected examples of successful gene therapy studies for prevention of acute cardia
been indicated, although multiple mechanisms may be involved. (*) denotes a study c
text; Ad: adenovirus).
Mechanism Therapeutic gene
Cytoprotection, anti-oxidant NFkB ODN decoy
eNOS
Mn-SOD
HO-1
Inhibition of adhesion molecules ICAM-1 ODN decoy (+anti-LFA-1 Ab)
Cytokine inhibition TNFRp55-Ig
IL-1R type 2-Ig
IL-1RA (*)
IL-17Ig
IL-18 binding protein
Immune deviation IL-4
IL-10
vIL-10
IL-4 + IL-10
IL-13
TGFb1
Chemokine inhibition vMIP-II, MC148
8ND-RANTES/CCL5
Inhibition of T cell costimulation CTLA4Ig
CD40Ig
CTLA4Ig + CD40Ig
PDL1Ig
Tolerance induction Donor MHC class I
IDOvirus (AAV)-mediated gene transfer into mouse hearts [2].
Stable expression of the delivered gene in vivo opens new
opportunities for gene therapy to prevent chronic rejection.
The present review discusses various gene therapy
approaches that have been tested with positive results in
cardiac transplant models (Fig. 1). A discussion of gene
therapy of xenotransplantation is beyond the scope of the
present review. This topic has been recently reviewed
elsewhere [3]. Gene transfer vectors most frequently used in
gene therapy studies in heart transplantation will be
discussed briefly in the following section.
2. Gene transfer vectors
Gene delivery vehicles include viral and nonviral vectors.
Overall, viral vectors are more efficient than nonviral but
they are also associated with more significant side effects.
Recombinant adenovirus vectors of the first generation
have been used in the vast majority of gene therapy studies
in heart transplantation (Tables 1 and 2). These vectors
efficiently deliver and express genes in the myocardium
(Fig. 2) and, somewhat less efficiently, in vascular endoth-
elium. However, first-generation adenovirus vectors encode
immunogenic viral proteins that trigger cytotoxic immune
responses leading to the elimination of the cells that express
the foreign gene. To circumvent this problem, so-called
‘gutless’ (or helper-dependent, high-capacity) adenovirus
vectors deleted in most or all of the viral genes have been
developed. We have shown that a ‘gutless’ adenovector
caused significantly less myocardial inflammation than a first-
generation adenovector in rat hearts [4].c allograft rejection (non-exhaustive list). The likely mechanism of action has
arried out in a nontransplant ischaemia—reperfusion model (abbreviations: see
Vector Model Ref.
HVJ-liposomes Rat [24]
Liposomes, Ad Rabbit, rat [15,16]
Ad Rabbit [16]
Ad Rat [18]
Liposomes Rat [14]
Ad Rat [21]
Ad Rat [20]
HVJ-liposomes Rat [19]
Ad Rat [22]
Ad Rat [23]
Ad Rat [27]
Ad Rabbit, rat [11,26]
Ad Rabbit [25]
Liposomes Rabbit [29]
Ad Rat [28]
Ad, liposomes Mouse, rabbit [10,25]
Liposomes Mouse [32]
Lentivirus Rat [9]
Ad Rat [34]
Ad Rat [35]
Ad Rat [36]
Ad Rat [40]
Retrovirus, Ad Mouse [43,44]
Ad Rat [38]
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Table 2
Selected examples of successful gene therapy studies for prevention of accelerated graft vasculopathy in arterial or cardiac allotransplant models (non-exhaustive
list). (*) denotes a study in which the donor heart was first placed in a syngeneic recipient, followed by a second transplantation into an allogeneic recipient 4 days
later (abbreviations: see text; Ad: adenovirus).
Mechanism Therapeutic gene Vector Model Ref.
Cytoprotection or anti-oxidant HO-1 Ad Rat aorta [55,56]
Bcl-2 (*) Ad Rat heart [58]
tPA Liposomes Rabbit heart [65]
SMC apoptosis, inhibition to cell proliferation Bcl-x ODN decoy Liposomes Mouse heart [57]
Soluble Fas Ad Rat aorta [60]
FasL Ad Rat carotid [61]
Anti-ERK1/2 decoy Liposomes Rat aorta [63]
CTLA4-FasL chimera Ad Mouse heart [64]
Anti-E2F decoy Liposomes Monkey heart [68]
Inhibition of extracellular matrix digestion Anti-MMP-2 ribozyme HVJ-liposomes Mouse heart [66]
Chemokine inhibition MCP-1 antagonist Liposomes Mouse heart [62]
Inhibition of T cell costimulation CD40Ig Ad Rat aorta [59]
Fig. 2. Adenovirus-mediated in vivo transfer of a GFP reporter gene into rat
myocardium. Myocytes represent the main cell type expressing GFP after gene
transfer into the heart.As mentioned above, AAV vectors have a potential for
stable gene expression in many organs including the heart
[2]. These vectors are poorly immunogenic and have been
safely used in clinical gene therapy trials in nontransplanted
patients. Conventional AAV vectors derived from AAV
serotype 2 have a broad tissue tropism, which results in
the predominant transduction of the liver after systemic
vector administration. Newer AAV vectors derived from
serotypes 1, 4, 5, 6, and 9 allow enhanced gene transfer into
the myocardium [5,6]. Ex vivo perfusion of an AAV-9 vector
into the donor heart achieved up to 72% myocardial gene
transfer efficiency 10 days after heart transplantation in
rodents [6]. Cardiac expression levels of the LacZ reporter
gene were unchanged 3 months after transplantation, with
no overt evidence of tissue toxicity.
Retrovirus vectors have a potential for stable gene
expression owing to chromosomal integration. Among retro-
virus vectors, lentivirus vectors have the unique ability to
deliver genes to nondividing cells. We have shown that a self-
inactivating, multiply attenuated lentivirus vector based on
human immunodeficiency virus type 1 (HIV-1) efficiently
delivered and expressed a GFP reporter gene in ratmyocardium and endothelial cells in vivo [7,8]. However,
lentivirus vectors caused significant myocardial inflammation
in our model.
Nonviral vectors including cationic lipids and liposomes,
alone or in conjunction with fusogenic proteins that facilitate
cell entry, such as those derived from the haemagglutinating
virus of Japan (HVJ; Sendai virus) can carry large DNA
sequences and are generally safer than viral vectors.
Liposomes have been successfully used to introduce genes
of interest into the donor heart [10,11]. The envelope of HVJ
alone efficiently delivered proteins, genes, and oligode-
oxynucleotides (ODN) to a majority of cultured neonatal
cardiac myocytes, whereas the corresponding vector lacking
the HVJ envelope delivered genes only to a few cells [12].
Recently, a multifunctional envelope-type nano-device
(MEND) was shown to enter cells via macropinocytosis,
escape lysosomal degradation, and mediate nuclear translo-
cation [13]. Gene transfer efficiency of this vector
approaches that of viral vectors.
A universal vector suitable for all gene therapy applica-
tions does not exist. The most appropriate vector for a given
application depends on both the therapeutic gene and the
target tissue. The biological effect of the encoded protein
determines whether transient or sustained gene expression is
desirable.
3. Immune responses and graft rejection
Early damage to the donor organ may result from brain
death of the donor, organ procurement, oxygen deprivation
during the organ preservation time, the surgical procedure
itself, and subsequent reperfusion injury. Graft endothelium
is particularly vulnerable to ischaemia—reperfusion injury,
which causes endothelial cell activation characterised by
upregulation of cell adhesion molecules. As a result,
leukocytes adhere to the endothelium and then accumulate
in the graft. Factors of the complement system become
activated, and neutrophils migrate into the graft, followed
by natural killer (NK) cells and macrophages. Early non-
specific inflammatory reactions are followed by specific
alloimmune responses that culminate in massive graft
infiltration by T cells, B cells, macrophages, and dendritic
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recognition by the host immune system have been described.
Donor-derived DC and monocytes/macrophages present in
the donor heart are transplanted together with the donor
heart. After transplantation, donor-derived DC leave the
graft, migrate to recipient lymph nodes and spleen, and
present donor antigen to recipient T cells directly. In
contrast, the indirect pathway of allorecognition includes
the migration of host DC into the graft, where they pick up
and process donor antigen, which is subsequently presented
to host T cells. It is believed that the direct pathway plays a
dominant role in acute rejection, whereas the indirect
pathway is more relevant to chronic rejection. Humoral
immune responses also participate in chronic rejection. Full
T cell activation by DC requires ‘costimulatory’ molecular
interactions of pairs of ligands and receptors expressed on
the surfaces of T cells and DC (see below).
A number of candidate genes that interfere with different
mechanisms of ischaemia—reperfusion injury and graft
rejection have been evaluated in cardiac transplant models.
Selected examples of genes that have shown evidence for
therapeutic benefit in these models are listed in Table 1. This
table is not intended to provide an exhaustive list of the
genes that have been tested, but to illustrate the variety of
potential therapeutic targets in this context.
4. Gene transfer of anti-inflammatory and
cytoprotective factors
Intercellular adhesion molecules (ICAM) are upregulated
on graft endothelial cells during ischaemia and reperfusion.
Hyperbaric introduction of antisense ODN with specific
affinity for ICAM-1 into the donor heart inhibited ischae-
mia—reperfusion injury and allograft rejection in a cardiac
transplant model in the rat [14]. Nitric oxide (NO) generated
by endothelial NO synthase (eNOS) is a key vasoprotective
molecule. eNOS gene transfer into the donor heart
attenuated ischaemia—reperfusion injury, leukocyte infiltra-
tion, and allograft rejection in a cardiac transplant model in
the rabbit [15]. Free radical scavengers neutralise reactive
oxygen species (ROS) generated during ischaemia and
reperfusion, as well as ROS produced by neutrophils and
monocytes/macrophages that infiltrate the graft. Adeno-
virus-mediated manganese-superoxide dismutase (SOD) gene
transfer into the donor heart mitigated ischaemia—reperfu-
sion injury after organ preservation and transplantation in a
cardiac transplant model in the rabbit [16].
Haem oxygenase (HO) is a cytoprotective enzyme that
catalyses the rate limiting step in haem degradation, which
results in the formation of carbon monoxide (CO), iron, and
biliverdin. The products of haem degradation have antiox-
idant, anti-inflammatory, anti-proliferative, and anti-apop-
totic effects. Local increase in CO may downregulate
macrophage activity and prevents apoptosis in endothelial
cells. The inducible isoform HO-1 is increased as an adaptive
response in various stress conditions including exposure to
haem, hyperoxia, and hypoxia. In these conditions, HO-1
activity contributes to diminishing the overall production of
ROS. The HO-1 system has been associated with cytoprotec-
tion in various pathological conditions including cardiovas-cular diseases, diabetes, inflammation and hypertension, as
reviewed elsewhere [17]. Sustained HO-1 induction delays
the onset of diabetes in NODmice. Human HO-1 gene transfer
attenuated angiotensin II- and tumour necrosis factor (TNF)-
mediated DNA damage in endothelial cells. Systemic HO-1
gene delivery using an adenoviral vector allowed long-term
allograft survival (>100 days) in up to 80% of cardiac
transplant recipients in a mouse model [18]. By comparison,
ex vivo HO-1 gene delivery to the donor heart was less
beneficial than systemic gene transfer, possibly due to lack of
immunosuppressive effects associated with HO-1 expression
in the spleen after systemic gene delivery.
5. Gene transfer of inhibitors of pro-inflammatory
cytokines
We and others have shown that gene transfer of inhibitors
of pro-inflammatory cytokines, such as IL-1, TNFa, IL-17, and
IL-18 moderately prolongs cardiac allograft survival in rodent
models [19—23]. The transcriptional factor nuclear factor-
kappaB (NFkB) is a key inflammatory mediator of endothelial
activation. ODN with specific affinity for NFkB attenuated
ischaemia—reperfusion injury in rat donor hearts preserved
at 4 8C in Euro-Collins solution during 16 h and reperfused for
1 h [24].
6. Gene transfer of immunoregulatory cytokines
Production of interferon g (IFNg) and other Th1 cytokines
has been associated with acute rejection. Conversely,
‘immune deviation’ towards Th2 cytokines, such as IL-4,
IL-10, IL-13, and transforming growth factor b (TGFb) has
been linked to improved graft survival. Consistent with this,
gene transfer-based overexpression of IL-4, IL-10, IL-13 or
TGFb1 in the donor heart moderately prolonged cardiac
allograft survival in rodent models [10,25—29]. While over-
expression of a single Th2 cytokine conferred modest
protection upon the graft, combined IL-4 and IL-10 gene
transfer allowed long-term cardiac allograft survival in
rabbits [29]. These results indicate synergistic effects of
the two immunosuppressive cytokines.
7. Gene transfer of chemokine antagonists
Chemoattractant cytokines (i.e., chemokines) play a
central role in the mobilisation and activation of leukocytes
in inflammatory conditions, including graft rejection [30].
Differential expression patterns of chemokines and chemo-
kine receptors have been observed in acute rejection of
cardiac and pancreatic islet allografts [31]. The RANTES/
CCL5 chemokine is expressed in cardiac grafts early after
transplantation. We have shown that gene transfer of an NH2-
terminally deleted RANTES/CCL5 mutant gene acting as a C—
C chemokine antagonist moderately prolonged cardiac
allograft survival in rats [9]. Similar results were observed
with gene transfer of the viral chemokine homologues MC148
and vMIP-II, which act as functional chemokine antagonists,
in a cardiac transplant model in rodents [32].
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Full activation of host T cells, the central mechanism of
allograft rejection, requires three distinct signals: (1) T
cell receptor (TCR) activation upon recognition of the
major histocompatibility complex (MHC)—peptide complex
on the surfaces of antigen-presenting cells (APC); (2)
costimulatory signals that arise from the interactions of
ligands and their corresponding receptors expressed on T
cells and APC, including CD28 and B7 (CD80/CD86), as well
as CD40 ligand (CD154) and CD40; and (3) secretion of
stimulatory cytokines, such as IL-12 [33]. Antigen pre-
sentation in the absence of strong costimulatory T cell
activation favours the development of a state of antigen-
specific T cell unresponsiveness (anergy), or primes T cells
for apoptosis. Cytotoxic T lymphocyte antigen-4 (CTLA4),
which is upregulated on T cells upon activation, modulates
T-cell costimulatory activation. Adenovirus-mediated ex
vivo gene transfer of a soluble CTLA4-immunoglobulin
fusion protein (CTLA4Ig) into the donor heart was
associated with detectable CTLA4Ig serum levels 120 days
after transplantation and long-term cardiac allograft
survival (>100 days) in a rat model [34]. These results
exemplify the notion that, while gene expression from
first-generation adenovirus vectors usually is short lived
due to immune responses to the vector, it may be markedly
prolonged in the case when the delivered gene encodes an
immunosuppressive peptide that inhibits these immune
responses. Recipients of long-term surviving grafts trans-
duced with the CTLA4Ig gene accepted a second cardiac
graft from the original donor strain in the absence of
pharmacological immunosuppression, while normally
rejecting third-party grafts. These findings suggest that
CTLA4Ig expressed in the graft induced donor-specific
hyporesponsiveness. Gene transfer of a soluble CD40Ig
fusion protein that blocks costimulatory CD40—CD154
interactions similarly prolonged cardiac allograft survival
in the same model [35]. However, expression of CTLA4Ig or
CD40Ig in the graft induced some degrees of general
immunosuppression due to spill-over of the soluble
chimeric protein into the systemic circulation. Interest-
ingly, combined gene transfer of CTLA4Ig and CD40Ig was
more effective than that of either gene alone [36].
CD40Ig treatment induced indefinite donor-specific
allograft acceptance in a complete MHC-mismatched
cardiac transplant model in the rat. The tolerogenic effect
was associated with induction of CD8+CD45+RC+ regulatory
T (Treg) cells, IFNg, and indoleamine 2,3-dioxygenase (IDO)
[37]. IDO is an IFNg-inducible enzyme that catalyses the
rate-limiting step in the catabolism of the essential amino
acid tryptophan, which is important for normal T cell
functions. Recent evidence suggests that IDO modulates T
cell responses to self antigens (autoimmunity), alloanti-
gens, and tumour antigens. Within cardiac allografts,
CD40Ig treatment induced selective IDO expression in
endothelial cells. Neutralisation of IFNg or IDO triggered
acute allograft rejection in CD40Ig-treated recipients.
These results suggest that inhibition of CD40—CD154
interactions results in the formation of allospecific Treg
cells that facilitate cardiac allograft acceptance via
induction of IFNg and endothelial IDO expression. We haveshown that adenoviral IDO gene transfer into DC inhibits
allogeneic T cell responses in vitro, and that IDO gene
transfer into rat donor hearts moderately prolongs cardiac
allograft survival in vivo [38].
Programmed death (PD) 1 is a CD28 homologue
expressed on activated T cells, B cells, and myeloid cells
[39]. Engagement of PD1 by its ligands, PDL1 and PDL2,
inhibits activated T cells. We have shown that adenoviral
gene transfer of a soluble PDL1Ig fusion protein into the
donor heart moderately prolongs cardiac allograft survival
in rats [40]. Together, these results suggest that gene
therapy modalities that interfere with T cell costimulatory
activation may confer significant protection upon the
graft. It should be noted, however, that these results likely
reflect the development of donor-specific hyporesponsive-
ness, rather than true immunological tolerance. In this
regard, it has been noted that cardiac allografts in
rodents, unlike in larger animals and humans, may provide
direct tolerogenic effects that facilitate graft acceptance
[41].
9. Transfer of donor MHC class I and II genes
MHC mismatch between the donor and recipient is a
major, albeit not exclusive mechanism of allograft rejection.
To induce ‘molecular chimerism’ and unresponsiveness to
donor MHC antigens, autologous cells genetically modified
with donor MHC class I or II genes were introduced back into
the recipient around the time of transplantation. Autologous
fibroblasts expressing donor MHC class I or II genes allowed
prolonged cardiac allograft survival in a mouse model [42].
Reconstitution of the host bone marrow with autologous
haematopoietic stem cells genetically modified with donor
MHC class I or II induced donor-specific T cell unresponsive-
ness in cardiac transplant models in rodents [43—46]. A
critical issue with these approaches, however, is stability of T
cell unresponsiveness induced by ‘molecular chimerism’
[47].
10. Induction of Treg cells
Treg cells modulate T cell activation in various contexts,
including auto- and alloimmunity. These cells promote
the development of antigen-specific immune tolerance,
and therefore facilitate the acceptance of grafts that
express their cognate antigens [48—50]. Foxp3 is the
master transcriptional regulator of Treg cell development.
foxp3 gene transfer into naı¨ve CD4+CD25 precursor cells
induced the formation of functional CD4+CD25+Foxp3+ Treg
cells that facilitated skin allograft acceptance in mice
[51]. Because Treg cells are antigen-specific, and because
the graft expresses multiple different antigens, induction
of Treg cells by foxp3 gene transfer would be most effective
if transferred unresponsiveness to defined antigens were
to expand to other antigens shared by the graft
[52]. This phenomenon, referred to as ‘infectious toler-
ance’, has been observed in tolerant systems in which
Treg cells constitute the central mechanism of tolerance
[53].
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An accelerated form of coronary artery disease char-
acterised by concentric intimal thickening and widespread
distribution of lesions across the coronary tree is the central
manifestation of chronic rejection of cardiac allografts.
Chronic immune reactions associated with perivascular
inflammation induce persistent endothelial cell activation
and secretion of growth factors, such as platelet-derived
growth factor (PDGF), which stimulates the proliferation of
vascular smooth muscle cells (SMC) leading to intimal
thickening. Nonimmunological factors such as drug-related
toxicity, metabolic abnormalities, and viral infections
(particularly cytomegalovirus) play contributory roles in
the pathogenesis of graft vasculopathy [54]. Selected studies
of gene transfer-based approaches to prevent transplant
vasculopathy are listed in Table 2.
Adenovirus-mediated gene transfer of the cytoprotective
enzyme HO-1 partially prevented antibody-induced graft
vasculopathy in aortic transplant models in rodents [55,56].
Antisense ODNwith specific affinity for Bcl-x, a mitochondrial
anti-apoptotic factor, also mitigated the development of
graft vasculopathy [57]. The underlying mechanism pre-
sumably involved increased apoptosis of SMC in intimal
lesions, leading to decreased lesion formation. Paradoxically,
overexpression of Bcl-2, a distinct mitochondrial anti-
apoptotic factor, also attenuated the development of graft
vasculopathy [58]. This was shown by first placing the donor
heart transduced with the Bcl-2 gene in a syngeneic recipient
to allow for Bcl-2 gene expression in the graft in the absence
of alloimmune responses, with re-transplantation of the graft
into an allogeneic recipient 4 days later. In other studies,
adenoviral gene transfer of CD40Ig [59], soluble Fas receptor
[60], or Fas ligand [61] partially prevented the development
of graft vasculopathy. Fas ligand acts by inducing apoptosis of
activated Tcells that express Fas receptor on their surfaces.
Monocyte chemoattractant protein-1 (MCP-1) is a potent
chemoattractant of monocytes-macrophages into graft
arterial lesions. Gene transfer of an NH2-terminally deleted
MCP-1 mutant gene reduced intimal thickening in an aortic
transplant model [62]. Other gene therapy approaches that
have shown protective effects against graft vasculopathy
include antisense ODN with specific affinity for mitogen-
activated protein kinase ERK1/2 [63], a signalling molecule
involved in cell survival and proliferation, gene transfer of a
chimeric CTLA4-FasL protein [64], and gene transfer of
tissue-type plasminogen activator (tPA) [65], a vasoprotec-
tive factor that is downregulated throughout the develop-
ment of graft vasculopathy. Matrix metalloproteinases (MMP)
digest extracellular matrix in the vessel wall, and therefore
allow for SMC migration into the intima and neointimal
formation. MMP-2 is persistently activated in the vessel wall
throughout the progression of graft vasculopathy. A ribozyme
against MMP-2 inhibited MMP-2 expression and the develop-
ment of graft coronary artery lesions in a rodent model [66].
Ribozymes are a class of RNA molecules that possess RNA
sequence-specific activity combined with catalytic activity.
They hybridise with a target mRNA, and cleave the
complementary mRNA [67].
Finally, double-stranded DNAwith specific affinity for E2F,
a transcription factor that plays a central role in cell cycleprogression, attenuated cell proliferation, intimal thicken-
ing, and graft coronary artery lesions 8 weeks after heart
transplantation in rhesus monkeys [68]. However, the long-
term efficacy of these approaches remains to be established.
12. Challenges toward clinical applications
Despite encouraging results in animal models, progress
toward clinical applications in gene therapy for transplanta-
tion has been slow. This can be explained by several factors,
including limitations of gene transfer vectors, an incomplete
understanding of the mechanisms of alloimmune activation,
and scarce data in non-human primate models. Immunosup-
pressive drugs currently used in clinical transplantation are
quite effective in preventing acute rejection, and therefore
it will be difficult for gene therapy to achieve improvement
on top of them.
Vector limitations include both poor gene transfer effi-
ciency and side effects. As already mentioned, however,
significant advances in vector development have been scored
recently. Over the past decade, rare adverse events caused by
viral vectors used in clinical trials in nontransplanted patients
have set back the field of gene therapy. In a gene therapy trial
of ornithine transcarbamylase (OCT) deficiency, a young man
died after receiving the highest dose of adenovirus vector in
the study [69]. The death was caused by an unusually strong,
systemic inflammatory syndrome leading to multi-organ
failure. It should be noted, however, that the first-generation
adenovector used in this study was more immunogenic than
last-generation adenovectors. More recently, the three
youngest patients in a retrovirus-based gene therapy trial of
X-linked severe combined immunodeficiency disorder (SCID-
X1) developed leukaemia due to insertional mutagenesis
caused by the retrovirus vector [70]. However, the leukaemia
found in these patients might be unique to this particular
disease because the genetic reconstitution of a very few
precursor cells results in the selective proliferation of immune
cells genetically corrected with the vector. Regardless, these
adverse events have highlighted the potential risks of viral
vectors. Clearly, gene transfer vehicles differ from pharma-
cological agents in many ways, including the definition of the
dose and biological activity, and the tissue distribution and
kinetics of the transgenic protein in vivo. These aspects of
gene therapy, together with the reproducibility of gene
delivery protocols, need to be characterised more precisely.
Little is known about the inter-individual variability in gene
transfer efficiency and the duration of transgene expression in
humans. This may depend on multiple factors, such as genetic
factors and pre-existing antibodies to the vector (e.g., as a
result of previous exposure to wild-type adenovirus).
While molecular mechanisms of immunological rejection
and tolerance are relatively similar in non-human primates
and humans, they differ in several important ways in rodents
and primates [71]. Stable tolerance induction is not achieved
routinely in large animals and humans. For practical reasons,
the vast majority of gene therapy studies in transplantation
have been carried out in rodents. These models are still
useful for initial feasibility studies of new vectors, gene
delivery protocols, and therapeutic genes. It will be
important to compare different vectors and genes directly
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variables. Based on results in these models, the most
promising modalities will be tested in more relevant monkey
models, starting with small feasibility studies, followed by
larger safety and efficacy studies. Prevention of chronic
rejection and graft vasculopathy should be assessed long-
term (e.g., 1—2 years after transplantation), not just after
2—3months, as in previous studies [68]. Potential side effects
of immunomodulatory genes including opportunistic infec-
tions, cancer, and induction of autoimmune responses should
be investigated. Obviously, gene therapy modalities must be
compared directly with current immunosuppressive regimens
in well-controlled pre-clinical studies in monkeys. Beneficial
combinations of the two approaches must be tested. The
development of a new gene therapy modality from small
animal models to pre-clinical studies may well require a
decade (or longer, if limited effort is devoted to achieving
this goal).
13. Future prospects
The real challenge in transplantation is prevention of
chronic rejection. The recent development of vectors
capable of expressing a gene for extended periods of time
has provided new tools to achieve this goal. AAV vectors offer
several advantages, including high efficiency, differential
tissue targeting by different AAV serotypes, stable gene
expression, negligible tissue inflammation, and a good safety
profile, as documented in several clinical trials in non-
transplanted patients [72]. Newer nonviral vehicles repre-
sent a valuable alternative, as they are nearly as efficient as,
and potentially safer than, viral vectors. Desirable features
of future vectors include regulation of gene expression levels
(‘gene dosage’) to match clinical needs, tissue-specific gene
expression, and multi-cistronic vectors expressing multiple
genes. Regulatable vectors controlled by oral intake of
doxicycline or other agents have been tested successfully in
vivo [73] but still need to be optimised for clinical
applications.
The most effective gene to be introduced into the donor
heart, or to be employed in cell-based gene therapy using DC
[74], stem cells or other bone marrow-derived cells still
needs to be identified. In previous studies, genes encoding
immunomodulatory cytokines or inhibitors of pro-inflamma-
tory cytokines and chemokines have shown only modest
protective effects. Genes encoding inhibitors of T cell
costimulatory activation, such as CTLA4Ig and CD40Ig, have
provided more encouraging results, likely due to direct
inhibition of alloreactive T cells. Simultaneous blockade of
multiple Tcell costimulatory pathways has shown additive or
synergistic effects [75]. The emerging role of Treg cells in
antigen-specific tolerance induction has fostered the devel-
opment of gene therapy approaches that focus on the
generation and/or functional enhancement of these cells.
In conclusion, the conceptual advantage of gene therapy
in transplantation is that localised overexpression of the
protective gene within the graft may promote a state of local
immune privilege, and therefore reduce the need for general
immunosuppression. Alternatively, gene therapymay attenu-
ate alloimmune responses through the generation of Treg cellsand regulatory DC. Because expression of a protective gene
may last for extended periods of time, gene therapy has a
potential for preventing chronic rejection. Improved efficacy
may be achieved by combining different modalities, e.g.,
expression of multiple therapeutic genes from a multi-
cistronic vector within the graft, with concomitant transfer
of Treg cells and/or genetically modified DC. If clinical trials in
gene therapy of transplantation are started one day, it can be
anticipated that the role of gene therapy will be that of an
adjunct therapy. In fact, immunosuppressive drugs would still
be needed, at least temporarily. A role for gene therapy as a
sole treatment in heart transplantation is theoretically
conceivable, but it cannot be envisioned in the foreseeable
future.
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